DNA methylation as a new tool for the differential diagnosis between T‐ LBL and lymphocyte‐rich thymoma
The Journal of Pathology · 2024
DOI: 10.1002/path.6346 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology, 2024. Verfasst von Mehdi Latiri und 22 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. Hauptthemen laut MEDLINE: Thymoma, Thymus Neoplasms, DNA Methylation, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: INCA (Institut National du Cancer), Institut National Du Cancer.
Abstract (Originalsprache)
T‐lymphoblastic lymphoma (T‐LBL) and thymoma are two rare primary tumors of the thymus deriving either from T‐cell precursors or from thymic epithelial cells, respectively. Some thymoma subtypes (AB, B1, and B2) display numerous reactive terminal deoxynucleotidyl transferase‐positive (TdT + ) T‐cell precursors masking epithelial tumor cells. Therefore, the differential diagnosis between T‐LBL and TdT + T‐lymphocyte‐rich thymoma could be challenging, especially in the case of needle biopsy. To distinguish between T‐LBL and thymoma‐associated lymphoid proliferations, we analyzed the global DNA methylation using two different technologies, namely MeDIP array and EPIC array, in independent samples series [17 T‐LBLs compared with one TdT + lymphocyte‐rich thymoma (B1 subtype) and three normal thymi, and seven lymphocyte‐rich thymomas compared with 24 T‐LBLs, respectively]. In unsupervised principal component analysis (PCA), T‐LBL and thymoma samples clustered separately. We identified differentially methylated regions (DMRs) using MeDIP‐array and EPIC‐array datasets and nine overlapping genes between the two datasets considering the top 100 DMRs including ZIC1 , TSHZ2 , CDC42BPB , RBM24 , C10orf53 , and MACROD 2. In order to explore the DNA methylation profiles in larger series, we defined a classifier based on these six differentially methylated gene promoters, developed an MS‐MLPA assay, and demonstrated a significant differential methylation between thymomas (hypomethylated; n = 48) and T‐LBLs (hypermethylated; n = 54) (methylation ratio median 0.03 versus 0.66, respectively; p < 0.0001), with MACROD2 methylation status the most discriminating. Using a machine learning strategy, we built a prediction model trained with the EPIC‐array dataset and defined a cumulative score taking into account the weight of each feature. A score above or equal to 0.4 was predictive of T‐LBL and conversely. Applied to the MS‐MLPA dataset, this prediction model accurately predicted diagnoses of T‐LBL and thymoma. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
- Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.
- Aix-Marseille University, INSERM, TAGC, UMR1090, Equipe Labélisée Ligue Contre le Cancer, Marseille, France.
- Department of Molecular Medicine,Al-Jawhara Centre for Molecular Medicine,Genetics, and Inherited Disorders, Arabian Gulf University, Manama, Bahrain.
- Institute of Pediatric Hematology and Oncology, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.
- Department of Pathology, Hôpital Necker-Enfants Malades, Université Paris-Cité, Paris, France.
ORCID-Profile: Violaine Latapie, Aurore Touzart
Förderung
- INCA (Institut National du Cancer)
- Institut National Du Cancer
Zitieren
APA
Latiri, M., Belhocine, M., Smith, C., Garnier, N., Balducci, E., Pinton, A., Andrieu, G. P., Bruneau, J., Spicuglia, S., Jamain, S., Latapie, V., de Montpreville, V. T., Chalabreysse, L., Marx, A., Girard, N., Besse, B., Plass, C., Gibault, L., Badoual, C., …, & Touzart, A. (2024). DNA methylation as a new tool for the differential diagnosis between T‐ LBL and lymphocyte‐rich thymoma. The Journal of Pathology. https://doi.org/10.1002/path.6346
Vancouver
Latiri M, Belhocine M, Smith C, Garnier N, Balducci E, Pinton A, et al. DNA methylation as a new tool for the differential diagnosis between T‐ LBL and lymphocyte‐rich thymoma. The Journal of Pathology. 2024. doi:10.1002/path.6346
BibTeX
@article{Latiri2024,
author = {Latiri, Mehdi and Belhocine, Mohamed and Smith, Charlotte and Garnier, Nathalie and Balducci, Estelle and Pinton, Antoine and Andrieu, Guillaume P and Bruneau, Julie and Spicuglia, Salvatore and Jamain, Stéphane and Latapie, Violaine and de Montpreville, Vincent Thomas and Chalabreysse, Lara and Marx, Alexander and Girard, Nicolas and Besse, Benjamin and Plass, Christoph and Gibault, Laure and Badoual, Cécile and Macintyre, Elizabeth and Asnafi, Vahid and Molina, Thierry Jo and Touzart, Aurore},
title = {DNA methylation as a new tool for the differential diagnosis between T‐ LBL and lymphocyte‐rich thymoma},
journal = {The Journal of Pathology},
year = {2024},
doi = {10.1002/path.6346}
}
EUVIMED